Table 1

Baseline characteristics of the 275 out of 508 patients in the BeSt study with and without vertebral fractures after 5 years of treatment
Baseline characteristics Without vertebral fractures (n = 234) With vertebral fractures (n = 41) p-value
Age, mean ± SD years 53 (13) 60 (11) 0.001
Female gender, no. (%) 159 (68) 26 (63) 0.568
Symptom duration, median (IQR) weeks 24 (14-50) 23 (15-49) 0.673
DAS, mean ± SD 4.4 (0.9) 4.2 (0.7) 0.069
HAQ, mean ± SD 1.3 (0.6) 1.4 (0.7) 0.594
BMI, mean ± SD 26 (4) 25 (4) 0.545
ESR, mean ± SD 36 (19-56) 44 (26-57) 0.098
CRP, mean ± SD 20 (9-52) 30 (12-51) 0.298
RF positive, no. (%) 152 (65) 29 (71) 0.472
ACPA positive, no. (%) 148 (64) 24 (59) 0.543
Smoking yes, no (%) 80 (34) 21 (51) 0.037
Treatment strategy, no. (%) 0.833
Sequential monotherapy 67 (28.6) 9 (22)
Step-up therapy 48 (20.5) 10 (24.4)
Initial combo with prednisone 55 (23.5) 10 (24.4)
Initial combo with infliximab 64 (27.4) 12 (29.3)

IQR, inter quartile range; DAS, disease activity score; HAQ, Health assessment Questionnaire; BMI, body mass index ; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; ACPA, anti-cyclic citrullinated peptide antibodies.

Dirven et al.

Dirven et al. BMC Musculoskeletal Disorders 2012 13:125   doi:10.1186/1471-2474-13-125

Open Data